Amgen Inc.
NASDAQ:AMGNDrug Manufacturers - General
-$6.93 today
- Market cap
- $240.11B
- Beta
- 0.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $14.44
- Dividend yield
- 2.93%
Volume 2.58M
Average 2.76M
AMGN Interest Expense
Cost of servicing the company's debt during the period.
Amgen Inc.NASDAQ: AMGN
Interest Expense · Q2 FY2026 · quarter ended Jun 2026
Interest expense declines year over year
Q2 FY2026 interest expense of $673M fell 4.9% year over year, ahead of the -9.7% change in trailing-twelve-month interest expense. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at +25.1% a year.
Context
- Interest expense amounted to 7.5% of revenue in FY2025, down 1.9 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -4.9% holds above the trailing-twelve-month pace of -9.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 2.76B USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- +23.2%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.76B | -12.7% |
| FY2024 | 2024-12-31 | 3.16B | +9.7% |
| FY2023 | 2023-12-31 | 2.88B | +104.5% |
| FY2022 | 2022-12-31 | 1.41B | +17.5% |
| FY2021 | 2021-12-31 | 1.2B | — |
Interest Expense vs competitors
How AMGN compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.7% is the 8th highest of 10, against a peer median of -0.1%.
- Interest expense amounts to 7.0% of revenue for AMGN, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.88B USD | -0.1% | +9.1% | 4.4% | |
| LTM Jun 2026 | $2.7B USD | -4.7% | +29.2% | 4.2% | |
| LTM Jun 2026 | $2.67B USD | -9.7% | +25.1% | 7.0% | |
| LTM Sep 2026 | $1.77B USD | +7.2% | +8.4% | 2.8% | |
| LTM Jun 2026 | $1.73B USD | -12.6% | +15.4% | 3.5% | |
| LTM Jun 2026 | $1.39B USD | +26.0% | +12.5% | 2.5% | |
| LTM Jun 2026 | $1.26B USD | -1.0% | +12.2% | 1.9% | |
| LTM Jun 2026 | $979.6M USD | +7.6% | +33.9% | 1.2% | |
| LTM Sep 2026 | $798M USD | -10.7% | +52.1% | 0.8% | |
| LTM Jun 2026 | £690M GBP | +6.8% | -7.1% | 2.1% | |
| Peer median (excluding AMGN) | — | -0.1% | +12.5% | 2.5% | |
Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.98B | 26.32B | 28.19B | 33.42B | 36.74B |
| Cost of Revenue | 6.45B | 6.41B | 8.42B | 12.86B | 10.73B |
| Gross Profit | 19.53B | 19.92B | 19.78B | 20.57B | 26.01B |
| Gross Margin | 75.2% | 75.7% | 70.1% | 61.5% | 70.8% |
| Research & Development | 6.32B | 4.43B | 4.78B | 5.96B | 6.97B |
| Selling, General & Admin | 5.37B | 5.41B | 6.18B | 7.1B | 7.05B |
| Operating Expenses | 11.89B | 10.35B | 11.84B | 13.31B | 15.34B |
| Depreciation & Amortization | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B |
| EBITDA | 11.3B | 12.17B | 14.8B | 13.36B | 16.9B |
| EBITDA Margin | 43.5% | 46.2% | 52.5% | 40.0% | 46.0% |
| Operating Income | 7.64B | 9.57B | 7.9B | 7.26B | 10.68B |
| Operating Margin | 29.4% | 36.3% | 28.0% | 21.7% | 29.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.2B | 1.41B | 2.88B | 3.16B | 2.76B |
| Other Income / Expenses | (938M) | (2.22B) | (42M) | (2.65B) | (1.7B) |
| Income Before Tax | 6.7B | 7.35B | 7.86B | 4.61B | 8.98B |
| Pre-Tax Margin | 25.8% | 27.9% | 27.9% | 13.8% | 24.4% |
| Income Tax Expense | 808M | 794M | 1.14B | 519M | 1.27B |
| Net Income | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B |
| Net Margin | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| EPS (Basic) | 10.34 | 12.18 | 12.56 | 7.62 | 14.33 |
| EPS (Diluted) | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 |
| Weighted Avg Shares | 570M | 538M | 535M | 541M | 538M |
| Weighted Avg Shares (Diluted) | 573M | 541M | 538M | 541M | 542M |
Amgen Inc.
NASDAQ:AMGN
Intrinsic Alpha fair value
Locked
Current Price
$443.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.